RE:RE:Nice to see Short interest dropping quicklyAgree Rw 2023 could be a very transformative year for Medipharm and its shareholders.
There is also the proceeds ($6.4 million) from the Austrailian asset that was not included in the Q3 cash totals.
- Ended the quarter with $19.5M of cash which does not include $6.4M for the sale of the Australian facility.